SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias shares drew attention after reports of CEO Jensen Huangs admitted affair with a woman alleged to have ties to Chinese intelligence prompted the board to open an independent investigation. Traders debated whether the controversy could threaten Huangs leadership or pose a national-security risk, while many dip buyers argued it does not change Nvidias AI-chip business fundamentals.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A weaker-than-expected Q3 revenue report and sequential sales decline are driving IBRXs sharp selloff, with traders questioning ANKTIVAs commercial uptake and raising concerns about competition, cash burn, and possible dilution. The reaction is divided: some see the results as evidence of weak execution, while others argue the BCG-naive trial success and Israeli approval support longer-term growth.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims is in focus around its quarterly results and its Eli Lilly deal to offer branded obesity drugs through its platform. Traders are split on whether the expanded GLP-1 offering can support growth, with concerns that lower margins could offset the benefit; some also speculate about an earnings leak, without evidence.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Discussion centers on the FDAs pending decision on Capricors deramiocel application for Duchenne muscular dystrophy, with traders focused on HOPE-3 upper-limb data and a letter from trial investigators urging approval. Many expect approval and speculate about a short squeeze, while others stress the binary risk of a rejection or CRL amid lingering FDA concerns.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk shares are rallying into quarterly earnings, with traders pointing to heavy short interest and the possibility of a squeeze if results or guidance beat expectations. Some speculate about an earnings leak, but that is unconfirmed; others warn the pre-earnings pop could fade, citing the stocks history of sharp post-report moves.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs preliminary third-quarter results, which showed strong sales and EBITDA growth, alongside Brad Jacobs bullish conference-call comments, have renewed optimism around the building-products roll-up strategy. Traders celebrated the rebound and speculated about short covering, though some remain cautious after the stocks steep decline.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Concern over a congressional report alleging Webull understated its China tiesand related securities lawsuitsdominates discussion of the stocks weakness. Bulls call the claims misleading and view the selloff as a buying opportunity ahead of earnings, while bears worry the allegations could sustain a China-risk discount.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly results beat expectations and management raised its revenue outlook on continued BRIUMVI growth, but shares fell as traders debated a sell-the-news reaction and alleged short-selling pressure. The upcoming Phase 3 readout for subcutaneous BRIUMVI is a major focus for investors looking beyond the earnings report.

Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. Its strategy is powered by its proprietary software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic diseases. The company offers PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. The company was founded by Vivek Garipalli and Andrew Toy on July 17, 2014 and is headquartered in Wilmington, DE.

Clover Health Investments Corp - Ordinary Shares - Class A

Clover Health Investments Corp

Clover Health is drawing attention after traders reacted to strong Q3 results, improved full-year guidance, and continued profitability and membership growth. Bulls welcomed the results and renewed move above $5, while others questioned the muted reaction and the lack of concrete Counterpart Health software-revenue details.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Heavy selling is centered on concerns about Arrowheads commercial execution, with traders criticizing Redemplos sales and the companys losses while comparing its launch with Ioniss Tryngolza. Some see weak competitor sales as an opening for Redemplo, but others question whether uptake and revenue justify the companys valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Traders are attributing FIGRs sharp move to revised 2028 earnings expectations, though that explanation is not broadly corroborated in the discussion. The community remains split between optimism about growth and HELOC demand and concerns about crypto weakness, valuation, and short-selling pressure.

Earnings Preview: Figure Technology (FIGR) Q3 Earnings Expected to Decline

Figure Technology (FIGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Priority Technology (PRTH) Lags Q3 Earnings Estimates

Priority Technology (PRTH) delivered earnings and revenue surprises of -3.23% and +3.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Top 3 Crypto & Blockchain Stocks to Watch as Digital Finance Expands

Robinhood, Circle and Figure expand their blockchain footprints through stablecoins, tokenized assets and digital lending as institutional demand grows.

Marsh Q3 Earnings Beat Estimates on Consulting Growth Despite Higher Costs

Marsh's Q3 2026 earnings beat estimates as strong growth in Consulting and Risk and Insurance Services lifted revenues, despite rising operating expenses.

Here's Why You Should Hold VRSK Stock in Your Portfolio Now

Verisk's recurring subscription revenues, AI-driven innovations and insurance analytics growth support its prospects despite rising costs and market headwinds.

Notable Wednesday Option Activity: FIGR, RH, LAD

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Figure Technology Solutions Inc - Class A Common (Symbol: FIGR), where a total of 43,444 contracts have traded so far, representing approximately 4.3 million underlying s...

Here's Why Figure Technology (FIGR) Is a Great 'Buy the Bottom' Stock Now

Figure Technology (FIGR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Cipher Digital Extends Barber Lake Lease, Boosts Revenues Above $9B

CIFR extends Barber Lake lease to 20 years, lifting contracted revenues above $9B while revising delivery phases and cost-sharing terms.

Here's Why You Should Hold WEX Stock in Your Portfolio Now

WEX's diversified growth, AI-driven efficiencies and stronger cash flow support its outlook, even as transaction weakness and high debt pose risks.

Government & Commercial Markets Aid ICFI Amid Elevated Costs

ICF International's non-federal growth, stronger cash flow and lower debt are offsetting federal weakness and elevated direct costs as procurement remains slow.

Figure Technology Solutions, Inc. is a blockchain-native capital marketplace, which engages in connecting origination, funding, and secondary market activity. It operates through the following segments: FTI, Markets, and Other. The FTI segment offers Figure Connect which generates ecosystem and technology fees, and originates, sells, and securitizes home equity line of credit (HELOC) loans that it services. The Markets segment utilizes blockchain technology to develop an exchange for digital assets and credit, with new product offerings including providing interest-bearing stable coin deposits. The company was founded by Michael Scott Cagney and June Ou in 2018 and is headquartered in Reno, NV.

Figure Technology Solutions Inc. - Ordinary Shares - Class A

HOOD, COIN Price Targets Slashed – Bernstein Predicts Crypto Stocks May Bottom Around Earnings Season

Equity

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Bernstein cut price targets on Robinhood and Coinbase but maintained ‘Outperform’ ratings on Monday.</li><li>The firm said macro pressure and weak crypto sentiment were driving short-term declines.</li><li>Analysts saw a potential bottom forming around these companies' weak first-quarter earnings.</li></ul>Robinhood Markets Inc. (HOOD) and Coinbase Global Inc. (COIN) received price cuts from Bernstein on Monday morning, citing short-term pressure from geopolitics and weak sentiment in the crypto market.The brokerage lowered its price target on Robinhood from $160 to $130 and on Coinbase from $440 to $330, but reiterated an ‘Outperform’ rating on both the crypto equities, as per TheFly. Despite trimming price targets, Bernstein believes current circumstances present a good entry point into these stocks.&nbsp;<a href="https://stocktwits.com/symbol/COIN/sentiment">Coinbase's stock</a> was up 2% in pre-market trading. The stock closed over $161 on Friday. On Stocktwits, the retail sentiment around COIN remained in the ‘neutral’ territory, while chatter levels around it remained ‘high’ over the past day.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_30_at_9_14_54_AM_png_9fdc7bb7a7.webp" alt="Screenshot 2026-03-30 at 9.14.54 AM.png" width="942" height="90"><figcaption>COIN retail sentiment and message volume on March 30 as of 9:17 a.m. ET | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/HOOD/sentiment">Robinhood's stock</a> was also trading up 2% during pre-market hours. The stock closed at $66 on Friday. On Stocktwits, the retail sentiment around HOOD remained in the ‘bullish’ territory, while chatter levels around it remained ‘high’ over the past day.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_30_at_9_15_18_AM_png_671039cefb.webp" alt="Screenshot 2026-03-30 at 9.15.18 AM.png" width="946" height="110"><figcaption>HOOD retail sentiment and message volume on March 30 as of 9:17 a.m. ET | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Analysts Think Crypto Stocks May Be Nearing A Bottom</h2>“The combination of geopolitics and temporary crypto weakness is offering big discounts on crypto stocks,”&nbsp;Bernstein noted, adding that both companies provide exposure to trillion-dollar markets with significant long-term growth potential.&nbsp;The firm said that the industry might be reaching a tipping point.&nbsp;It anticipates crypto stocks to bottom around the approaching weak first-quarter earnings cycle, indicating that the present weakness is a late-stage correction rather than a long-term decline.&nbsp;However, the cautious optimism goes beyond Robinhood and Coinbase. Bernstein said the&nbsp;overall&nbsp;crypto industry has greater potential, but values have fallen amid macroeconomic uncertainty. The firm also lowered&nbsp;Figure Technology (FIGR) price target to $67 from $72.As part of a larger portfolio reorganization last week,&nbsp;Cathie Wood’s&nbsp;ARK Investment Management also&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cathie-wood-dumps-blsh-shares-as-ark-trims-tech-stocks-including-nda/cZ3xi2yRImt">reduced</a> its stake in cryptocurrency firms such as Block Inc. (XYZ), Bullish (BLSH), and Coinbase.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-fed-policy-trap-jordi-visser/cZER8nBRINc">Fed’s ‘D.O.G.E. 2.0’ Trap Could Be Bitcoin’s Moment, Says Veteran Strategist</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Robinhood logo is displayed on a smartphone with Bitcoin logo in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Although the crypto industry has greater potential, values have fallen amid macroeconomic uncertainty, according to the research firm.

Coinbase Global Inc

Figure Technology Solutions Inc

Robinhood Markets Inc

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Feed

News

Sentiment

Earnings

Fundamentals

Info

FIGR News